initi thought sirtex
ep accret potenti
announc plan acquir sirtex medic strateg
deal would extend var reach intervent oncolog well-
establish radiat solut financi see ep accret
exit modest assumpt although announc met
mix review base headwind worst appear behind
sirtex pro-forma balanc sheet still support upsid
deal recap term valuat expect close propos acquisit
price per share translat total equiti valu approxim
use current aud/usd rate base forward top-lin ebitda estim
report report all-in purchas price equat
forward sale forward ebitda transact fund cash
debt target close date may
medic srx-asx nc lead provid radiotherapi solut focus
intervent oncolog io minim invas target cancer therapi compani
sir-spher resin microspher use perform select intern radiat
therapi sirt treat unresect metastat liver tumor primari colorect cancer
sirtex secur clearanc us eu australia along widespread
reimburs medicar unit healthnet other us result signific
growth sever measur past year activ site increas
compound-annual-growth-rate dose compound-annual-growth-rate revenu sinc
headwind self-caus larg behind compani recent srx
growth stall busi incur sever headwind inclus grow
competit london-bas btg theraspher liver/kidney cancer although
growth trajectori srx therapi versu btg theraspher certainli show continu
momentum toward latter growth impact last year stem sever miss-step
prior manag includ foxfir global analysi fail meet
endpoint present studi ceo termin follow alleg insid
trade signific level sale departur co recent re-evalu
 portfolio hire new manag stem salesforc departur
strateg rational expand sirt util tp new indic
look beyond stumbl srx steadili grown center footprint util
core indic combin metastat liver case one key growth limit
srx limit invest treatment plan softwar tp play
signific role work dosimetri phase sirt var strateg goal
drive synergi sizabl tp presenc understand alreadi file
applic clearanc veloc platform beyond tp synergi also
continu pursu addit indic combin therapi cancer
financi back-of-envelop point ep potenti
merger model make follow key assumpt srx top-lin growth
adjust om profil cash-to-debt mix cost debt also
bake-in modest revenu synergi cost synergi gradual improv exit
analysi point toward ep accret increas
gradual improv like exceed cost capit given
prevail rate high cash compon transact
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
page
pleas see import disclosur inform page report
purchas price allocationamtsaccret esynergi ecurr synergi synergi srx-asx revenu margin eoffer equiti valu revenu growth srx-asx adjust revenu growth srx-asx net interest expens ebita ev adjust ebita effect tax ebita structureamtspre-d dilut share ebita adj ebitda int rate price-to-earnings eyear principl pre-tax cash outlay interest addit int share revenu synergi share pre-tax capitalamtsless book valu pre-tax pro-forma exist tax exist price adjust ni fix asset share exist intang cash amort ep accretion/ dilut amort ep accretion/ dilut net exist debt ratio xannual amoritz debt ratio xgoodwil intang amort
headquart palo alto california lead provid integr system treat cancer radiat
therapi one premier supplier x-ray tube diagnost imag applic compani sell direct sale forc
rep combin direct sale independ distributor intern april compani
known varian associ inc spun instrument busi semiconductor equip busi stockhold separ
compani origin compani retain medic system busi chang name varian medic system inc
anthoni petron cfa certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat specif
recommend view express research report
raj denhoy certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
christian moor certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
catherin poulin-filion certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat specif
recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur
regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
page
pleas see import disclosur inform page report
jefferi franchis pick includ stock select among best stock idea equiti analyst month period stock select
base fundament analysi may take account factor analyst convict differenti analysi favor risk/reward
ratio invest theme jefferi analyst recommend jefferi franchis pick includ buy rate stock number
vari depend analyst recommend inclus stock ad new opportun aris remov reason
inclus chang stock met desir return longer rate buy and/or trigger stop loss stock day volatil
bottom quartil stock continu stop loss remaind stop franchis pick intend
repres recommend portfolio stock sector base may note believ pick fall within invest style
growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make invest decis base
upon specif invest object financi situat util financi advisor deem necessari past perform
financi instrument recommend report taken indic guarante futur result price valu
incom financi instrument mention report rise well fall may affect chang econom financi
polit factor financi instrument denomin currenc investor home currenc chang exchang rate may
advers affect price valu incom deriv financi instrument describ report addit investor secur
adr whose valu affect currenc underli secur effect assum currenc risk
note box rate price target histori chart repres action past three year analyst initi
compani made chang rate price target compani discontinu coverag compani
import disclosur inform compani recommend report pleas visit websit http //javatar bluematrix com/sellside/
